Hepatitis associated with micafungin use in a preterm infant

Journal of Perinatology

Volumn 29, Issue 4, 2009, Pages 320-322

  King, K Y ^a   Edwards, M S ^a   Word, B M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMPHOTERICIN B; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; MICAFUNGIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD CULTURE; CANDIDA ALBICANS; CANDIDEMIA; CANDIDIASIS; CASE REPORT; CHOLESTASIS; DRUG WITHDRAWAL; FEMALE; HUMAN; NEWBORN; PARTIAL THROMBOPLASTIN TIME; PREMATURITY; TOXIC HEPATITIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ALANINE TRANSAMINASE; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPARTATE AMINOTRANSFERASES; CANDIDIASIS; CHOLESTASIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ECHINOCANDINS; FEMALE; FUNGEMIA; HEPATITIS, TOXIC; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES; LIPOPEPTIDES; LIVER FUNCTION TESTS;

EID: 63649154126     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/jp.2008.197     Document Type: Article

References (9)

1. Heresi GP, Gertsmann DR, Reed MD, van den Anker JN, Blumer JL, Kovanda L et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J 2006; 25: 1110-1115.
2. Micafungin (Mycamine) for fungal infections. In: Abramowicz M (ed). The Medical Letter on Drugs and Therapeutics, Vol. 47, 2005, p 51.
3. Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: A phase III randomized double-blind trial. Lancet 2007; 369: 1519-1527.
4. Seibel NL, Schwartz C, Arrieta A, Flynn P, Shad A, Albano E et al. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 2005; 49: 3317-3324.
5. Hope WW, Seibel NL, Schwartz CL, Arrieta A, Flynn P, Shad A et al. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother 2007; 51: 3714-3719.
6. Product label for Mycamine(micafungin sodium) injection, powder, lyophilized, for solutionfor intravenous use. Initial U.S. Approval: 2008; http://165.112.6.82/dailymed/fda/ fdaDrugXsl.cfm?id=6635&type=display Updated Jan 2008.
7. Committee for Medicinal Products for Human Use. Summary of Positive Opinion for Mycamine. European Medicines Agency: London, 2008.
8. Sirohi B, Powles RL, Chopra R, Russell N, Byrne JL, Prentice HG, et al. A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 38: 47-51.
9. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, Mullane KM, Vazquez J, Anaissie EJ et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 2005; 24: 654-661.